Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
Uncategorized
October 5, 2023
![img: Featured](/wp-content/themes/neurocrine/assets/img/feature-5.jpg)
Uncategorized